- Home
- TCBS vs BRNS Comparison
TCBS vs BRNS Comparison
Compare TCBS & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCBS | BRNS |
|---|---|---|
| Founded | 1934 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.6M | 24.1M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TCBS | BRNS |
|---|---|---|
| Price | $16.60 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 2.0K | ★ 21.2K |
| Earning Date | 04-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.18% | N/A |
| EPS Growth | ★ 327.27 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $52.61 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.10 | $0.51 |
| 52 Week High | $20.00 | $2.91 |
Technical Indicators
Market Signals| Indicator | TCBS | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 56.66 |
| Support Level | $16.13 | $0.66 |
| Resistance Level | $16.62 | $0.75 |
| Average True Range (ATR) | 0.21 | 0.06 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 58.43 | 57.43 |
Price Performance
Historical ComparisonAbout TCBS Texas Community Bancshares Inc.
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans, commercial real estate loans, and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer, and other.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.